[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569280":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":45,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":45,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":63,"whyStopped":45,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: Psilocybin and intravenous (IV) midazolam","EXPERIMENTAL","Psilocybin (25 mg) + IV midazolam",[13,14],"Drug: Psilocybin","Drug: Midazolam",{"label":16,"type":10,"description":17,"interventionNames":18},"Group 2: Psilocybin and IV saline","Psilocybin (25 mg) + IV saline (placebo for midazolam)",[13,19],"Drug: Saline",{"label":21,"type":10,"description":22,"interventionNames":23},"Group 3: Psilocybin and IV midazolam","Psilocybin (1 mg\u002Fcontrol) + IV midazolam",[13,14],{"label":25,"type":10,"description":26,"interventionNames":27},"Group 4: Psilocybin and IV saline","Psilocybin (1 mg\u002Fcontrol) + IV saline",[13,19],[29,37,41,46],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Psilocybin","25mg of psilocybin",[9,16],[35,36],"Psilocybine","Psilocibin",{"type":30,"name":31,"description":38,"armGroupLabels":39,"otherNames":40},"1mg of psilocybin",[21,25],[35,36],{"type":30,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Midazolam","The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.",[9,21],null,{"type":30,"name":47,"description":48,"armGroupLabels":49,"otherNames":45},"Saline","Saline will be administered as a placebo for midazolam",[16,25],[51],{"name":52,"affiliation":5,"role":53},"Charles Raison, MD","PRINCIPAL_INVESTIGATOR",[55],{"name":56,"role":57,"phone":58,"phoneExt":45,"email":59},"RECAP Study Contact","CONTACT","608-263-4852","recap2@psychiatry.wisc.edu",[61],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":45},"UW School of Medicine and Public Health","RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-89.40123,43.07305,{"lat":73,"lon":72},{"type":76,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR",[78],{"name":79,"class":80},"Vail Health Foundation","UNKNOWN","100569280","phase-1-the-recap2-study-midazolam-and-psilocybin-100569280",false,"NCT06692192","The RECAP2 Study: Midazolam and Psilocybin","Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)","Inclusion Criteria:\n\n* Age 18 to 65 years at screening, of any identified gender and racial\u002Fethnic group\n* Physically healthy; does not meet criteria for an exclusionary medical condition\n* English-speaking (able to provide consent and complete questionnaires)\n* Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder\n* Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)\n\nExclusion Criteria:\n\n* Exclusionary DSM-5 psychiatric diagnosis and\u002For active suicidal ideation\n* Exclusionary medical conditions\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Clinically significant electrocardiogram (ECG)\n* Use of psychotropic or CNS-altering medications within 3 months of screening\n* Hypertension or tachycardia",true,"ALL","18 Years","65 Years",{"count":93,"type":94},60,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.\n\nResearchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.\n\nParticipants will:\n\n* Receive one of four possible combinations of medications\n* Undergo an MRI\n* Complete questionnaires\n* Undergo transcranial magnetic stimulation (TMS) and EEG",[31],[101],"sub-optimal wellbeing","2026-03-31",{"date":104,"type":105},"2026-04-03","ACTUAL",{"date":107,"type":105},"2025-08-07",{"date":109,"type":94},"2027-12",{"name":5,"class":6},1]